Health Canada pledges more plant inspections and more transparency

Health Canada, which has been accused of not providing the public with enough info about quality concerns over the drugs sold there, says it will increase the number of plant inspections it will do and put more information online, the Toronto Star reports. "Transparency initiatives related to inspections are a key priority to Health Canada," the regulator said in a a letter last month to drug manufacturers about its plans. The agency has been criticized for not letting the public know about problems with Canada-based Apotex, which has been repeatedly cited by the FDA for manufacturing problems at its plants in Canada and India. Story | More

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.